Bhageria Industries Ltd: From Dyes to Solar to Pharma – Jack of All Trades, Master of “Let’s See”

1. At a Glance

Bhageria Industries Ltd (BIL), born in 1989, began life selling dyes and now wants to sell everything—colors, electricity, and even Vitamin B12 derivatives. FY25 revenue stood at ₹640 crore with ₹45.7 crore PAT, giving it a neat P/E of 18x—not bad, but not exactly rainbow bright either. Promoters hold a chunky 71.8%, so clearly they’re not letting outsiders play Holi with their colors.

2. Introduction

Imagine a Gujarati thali—dye intermediates are the dal, solar is the khichdi, and pharma is the surprise chocolate brownie. That’s Bhageria Industries. The company started with Vinyl Sulphone and H-Acid, expanded into sulphuric acid, pigments, added solar plants in Chennai and Ahmednagar, and is now cooking up pharma raw materials.

The irony? Every new foray is sold as “game-changing,” but revenues have remained steady around ₹500–₹600 crore for years. Like a student with endless hobbies—guitar, coding, cooking—but average marks in all subjects.

Still, FY25 did show sparks: 40% sales growth in Q1 and PAT doubling. If execution sustains, maybe this isn’t just a Holi gulal business but a serious specialty chemicals and green energy player in the making.

3. Business Model – WTF Do They Even Do?

• Chemicals (94% revenue): Dyes, intermediates (Vinyl Sulphone 3,600 MTPA, H-Acid 4,800 MTPA, J-Acid & Tobias Acid 4,500 MTPA), pigments, and sulphuric acid (300 TPD).
• Solar (6% revenue): 30 MW plant in Ahmednagar (tariff ₹4.41/unit for 25 years) + 3.78 MW at Chennai. EPC contracts too—bagged a ₹104 Cr project in Bahrain.
• Pharma (coming soon): API intermediates, focusing on Vitamin B12 derivatives. Capex ₹50 crore, due by March 2025.

Customers: Huntsman, Everlight. Top 10 customers contribute 55–60% of chemical revenue (translation: concentration risk).

So, dyes bring the bread, solar brings a few crumbs, and pharma is the jam they’re hoping will sweeten margins.

4. Financials Overview

Commentary: Q1 looked like a blockbuster sequel after FY23’s flop show. But QoQ drop shows the movie may not run for 100 days.

5. Valuation – Fair Value Range Only

• P/E Method: FY25 EPS = ₹10.5. At CMP ₹187 → P/E ≈ 18x. Industry ~19x. Fair range: ₹170–₹210.
• EV/EBITDA Method: EV = ₹834 Cr; EBITDA ≈ ₹88 Cr → EV/EBITDA ≈ 9.5x. Peers 8–12x. Fair range: ₹160–₹200.
• DCF Method: Assume 10% revenue CAGR,